Onconetix Announces 1-for-10 Reverse Stock Split to Maintain Nasdaq Listing

summarizeSummary

Onconetix announced a 1-for-10 reverse stock split, effective May 21, 2026, to meet Nasdaq's minimum bid price requirement and avoid delisting.

check_boxKey Events

• Reverse Stock Split Finalized

  The Board of Directors approved a 1-for-10 reverse stock split, effective May 21, 2026, following shareholder authorization on April 30, 2026.

• Nasdaq Compliance Measure

  The primary purpose of the reverse split is to bring the company into compliance with Nasdaq's minimum bid price requirement, preventing potential delisting.

• Significant Share Count Reduction

  The reverse split will reduce the number of outstanding common shares from approximately 11.4 million to 1.14 million.

• Cash for Fractional Shares

  No fractional shares will be issued; stockholders entitled to fractional shares will receive a cash payment based on the closing price prior to the effective date.

auto_awesomeAnalysis

Onconetix has finalized a 1-for-10 reverse stock split, effective May 21, 2026, primarily to regain compliance with Nasdaq's minimum bid price requirement. This action follows shareholder approval on April 30, 2026, and is a critical step for the company to maintain its stock exchange listing. The company has previously disclosed a going concern warning and significant dilution, and its stock is currently trading near 52-week lows, underscoring the urgency and defensive nature of this move.